KS Biomedix releases Phase II data

KS Biomedix (LSE:KSB) said that in its 131-patient Phase II study of CBF-BS2, a a naphthoquinone derivative, to treat rheumatoid arthritis, swollen joint counts were significantly reduced at 15 mg (p=...